Benítez Sònia, Camacho Mercedes, Arcelus Rosa, Vila Luís, Bancells Cristina, Ordóñez-Llanos Jordi, Sánchez-Quesada José Luis
Department of Biochemistry and Inflammation Mediators Laboratory, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, C/ Antoni Maria Claret 167, Barcelona 08025, Spain.
Atherosclerosis. 2004 Dec;177(2):299-305. doi: 10.1016/j.atherosclerosis.2004.07.027.
Electronegative low-density lipoprotein (LDL(-)) is a plasma-circulating LDL subfraction with proinflammatory properties that induces the production of chemokines in cultured endothelial cells. However, the specific mechanism of LDL(-)-mediated chemokine release is presently unknown. A characteristic feature of LDL(-) is an increased content of lysophosphatidylcholine (LPC) and non-esterified fatty acids (NEFA). The effect of increasing amounts of LPC and NEFA associated with LDL on the release of chemokines by endothelial cells was studied. Total LDL was subfractionated by anion-exchange chromatography in electropositive (LDL(+)) and LDL(-). LDL(-) contained two-fold more LPC and NEFA than LDL(+) and induced two- to four-fold more (p < 0.05) interleukin-8 (IL-8, 11.5 +/- 8.2 ng/10(5) cells) and monocyte chemotactic protein-1 (MCP-1, 10.8 +/- 3.8 ng/10(5) cells) release by human umbilical vein endothelial cells (HUVEC) than LDL(+) (IL-8: 3.4 +/- 1.5 ng/10(5) cells, MCP-1: 5.8 +/- 2.9 ng/10(5) cells). The content of LPC and NEFA in LDL(+) was increased by enzymatic treatment with secretory phospholipase A(2) (sPLA(2)) at 5 ng/mL or 20 ng/mL or by incubation with NEFA at 2 mmol/L. Modification of LDL(+) by both methods did not result in oxidative modification as demonstrated by the lack of change in antioxidants, conjugated dienes and malondialdehyde content. sPLA(2) treatment resulted in an increase in LPC and NEFA in LDL(+) which enhanced its ability to release IL-8 and MCP-1 by HUVEC in a concentration-dependent manner (sPLA(2)(5)-LDL; IL-8: 7.1 +/- 3.8ng/10(5) cells, MCP-1: 8.0 +/- 5.1 ng/10(5) cells; sPLA(2)(20)-LDL; IL-8: 20.8 +/- 11.2 ng/10(5) cells, MCP-1: 15.0 +/- 7.5 ng/10(5) cells). NEFA loading of LDL(+) also favored the release of IL-8 and MCP-1 (IL-8: 7.8 +/- 6.1 ng/10(5) cells, MCP-1: 8.4 +/- 2.7 ng/10(5) cells, p < 0.05 versus LDL(+)). These effects were observed when modified LDL(+) reached a content of LPC and/or NEFA similar that of LDL(-). These data indicate that non-oxidized polar lipids associated with LDL promote an inflammatory response in endothelial cells and suggest that increased NEFA and LPC could be involved in the inflammatory activity of LDL(-).
带负电的低密度脂蛋白(LDL(-))是一种具有促炎特性的血浆循环低密度脂蛋白亚组分,可诱导培养的内皮细胞产生趋化因子。然而,目前尚不清楚LDL(-)介导趋化因子释放的具体机制。LDL(-)的一个特征是溶血磷脂酰胆碱(LPC)和非酯化脂肪酸(NEFA)含量增加。研究了与LDL相关的LPC和NEFA含量增加对内皮细胞趋化因子释放的影响。通过阴离子交换色谱法将总LDL分离为带正电的LDL(+)和LDL(-)。LDL(-)中的LPC和NEFA含量是LDL(+)的两倍,并且诱导人脐静脉内皮细胞(HUVEC)释放白细胞介素-8(IL-8,11.5±8.2 ng/10(5)个细胞)和单核细胞趋化蛋白-1(MCP-1,10.8±3.8 ng/10(5)个细胞)的量比LDL(+)多两到四倍(p<0.05)(LDL(+):IL-8:3.4±1.5 ng/10(5)个细胞,MCP-1:5.8±2.9 ng/10(5)个细胞)。用5 ng/mL或20 ng/mL的分泌型磷脂酶A(2)(sPLA(2))进行酶处理或与2 mmol/L的NEFA孵育可增加LDL(+)中LPC和NEFA的含量。两种方法对LDL(+)的修饰均未导致氧化修饰,这可通过抗氧化剂、共轭二烯和丙二醛含量无变化来证明。sPLA(2)处理导致LDL(+)中LPC和NEFA增加,从而以浓度依赖的方式增强其诱导HUVEC释放IL-8和MCP-1的能力(sPLA(2)(5)-LDL;IL-8:7.1±3.8 ng/10(5)个细胞,MCP-1:8.0±5.1 ng/10(5)个细胞;sPLA(2)(20)-LDL;IL-8:20.8±11.2 ng/10(5)个细胞,MCP-1:15.0±7.5 ng/10(5)个细胞)。LDL(+)加载NEFA也有利于IL-8和MCP-1的释放(IL-8:7.8±6.1 ng/10(5)个细胞,MCP-1:8.4±2.7 ng/10(5)个细胞,与LDL(+)相比p<0.05)。当修饰后的LDL(+)达到与LDL(-)相似的LPC和/或NEFA含量时,观察到了这些效应。这些数据表明,与LDL相关的未氧化极性脂质可促进内皮细胞的炎症反应,并提示NEFA和LPC增加可能参与LDL(-)的炎症活性。